The interaction between the triazolothienodiazepine
WEB 2086 and the in vitro and in vivo bronchopulmonary effects of
PAF-acether and active/passive
anaphylaxis in the guinea-pig was studied.
WEB 2086 (1-100 nM) inhibited
PAF-acether (10-100 ng)-induced bronchoconstriction and TXB2 release from isolated and perfused guinea-pig lungs without affecting the response to 100 micrograms
arachidonic acid. In addition, 1-10 microM
WEB 2086 significantly reduced
antigen-induced TXB2 and histamine release from lungs from actively and passively sensitized guinea-pigs. In the presence of the
lipoxygenase inhibitor nordihydroguaiaretic acid (NDGA),
mepyramine,
methysergide,
indomethacin and
atropine,
WEB 2086 (20-50 microM) inhibited by 30-40% the residual contraction of lung parenchyma strips from guinea-pigs actively sensitized by 0.1-10 micrograms
antigen. In vivo,
WEB 2086 (0.1-1 mg/kg) reversed or abolished the bronchoconstriction,
hypotension,
thrombocytopenia and
leukopenia evoked by perfusion of
PAF-acether (3 or 44 ng/kg per min). At 3 mg/kg,
WEB 2086 also markedly decreased the bronchoconstriction and
leukopenia induced by 100 micrograms/
kg antigen in
mepyramine (5 micrograms/kg)-treated passively sensitized guinea-pigs. In contrast,
WEB 2086 was ineffective against active
anaphylaxis in vivo. These results demonstrate that
WEB 2086 antagonizes the bronchopulmonary effects due to
PAF-acether and to
anaphylactic shock in the guinea-pig.